Prof. Johann Bauer

This small, early-stage study tested an experimental cancer drug called rigosertib in adults with a rare, severe skin condition (RDEB) who had developed an aggressive, hard-to-treat skin cancer. The main goals were to see if the drug could shrink the cancer and to check how safe …